Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Assessing the role of intratumoral microbiota in therapy responses using patient-derived tumor-on-chip

Project description

3D tumour-on-chip supports study of tumour microbiota and drug resistance

Microbiota are increasingly recognised as playing essential roles in health and disease in many organ systems. The tumour microenvironment is no exception. Intratumoural microbiota may modulate anti-cancer-drug resistance – a significant challenge in oncology – particularly resistance to immunotherapies such as immune checkpoint inhibitors. Unfortunately, scientists lack the appropriate experimental methods to investigate this phenomenon. As part of the Cancer Mission cluster of projects on understanding tumour-host interactions, the EU-funded Arturo project aims to bridge this gap, thanks to an innovative state-of-the-art 3D tumour-on-chip model. It will help scientists better understand the role of patient-derived bacteria and their signals on tumours and tumour drug responses.

Objective

"This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)"".
Challenge: Primary or acquired resistance to therapies is a major challenge in oncology. Recent research suggests that intratumoral microbiota may contribute to anti-cancer drug resistance, in particular to immunotherapies such as immune checkpoint inhibitors (ICI). However, experimental approaches to address the role of microbiota in human cancers are lacking.
Solution: Project ARTURO will ethically tackle this problem by using an innovative state-of-the-art 3D tumor-on-chip (ToC) model, as part of the emerging field of Micro-Physiological Systems (MPS).
Plan: The role of patient-derived bacteria, and of their postbiotics and released extra-cellular vesicles, in tumor ecosystem behaviors and drug responses, will be deciphered by integrating clinical data, omics analysis, and novel ToC-based information (by live imaging and single-cell transcriptomics). The development of advanced computational methods to extract ToC-based information constitutes a major force and innovation in the field, with high potential to accelerate future applications of ToC technology in clinics. The focus will be on two frequent poorly-understood cancer subtypes: non-small cell lung cancer (NSCLC) and invasive lobular breast cancer (ILC). End-users’ perspectives will be addressed using a co-design approach to develop ethically sound and evidence-based cancer-related innovation and health policies.
Impact: ARTURO results are expected to lead to a deep understanding of processes underpinning tumor-host interactions, helping to conceive novel microbiota-based intervention strategies, in particular for NSCLC and ILC patients. ARTURO will take social, ethnical, cultural, and gender aspects into account, facilitating the translation of ARTURO's innovations to clinical practice and co-design of policies. Ultimately, the ARTURO impacts will be far-reaching, contributing to future developments in cancer precision medicine and diagnostics and to the EU Mission – Cancer."

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project's classification has been validated by the project's team.

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-MISS-2023-CANCER-01

See all projects funded under this call

Coordinator

INSTITUT CURIE
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 057 745,00
Address
RUE D ULM 26
75231 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 474 182,50

Participants (6)

My booklet 0 0